What is HC Wainwright's Estimate for CLDX FY2024 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a note issued to investors on Thursday, November 7th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($2.39) per share for the year, up from their previous estimate of ($2.48). HC Wainwright has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for Celldex Therapeutics' Q4 2024 earnings at ($0.66) EPS and FY2025 earnings at ($3.02) EPS.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.13 million.

A number of other brokerages also recently issued reports on CLDX. The Goldman Sachs Group started coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a "neutral" rating and a $45.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. Citigroup started coverage on Celldex Therapeutics in a research note on Monday, October 7th. They issued a "buy" rating and a $70.00 target price for the company. Wolfe Research downgraded Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 27th. Finally, Wells Fargo & Company raised Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 26th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Celldex Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $62.25.

Celldex Therapeutics Price Performance

NASDAQ CLDX traded down $0.43 during mid-day trading on Monday, hitting $25.79. The stock had a trading volume of 357,527 shares, compared to its average volume of 869,801. Celldex Therapeutics has a twelve month low of $24.43 and a twelve month high of $53.18. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -10.16 and a beta of 1.60. The firm's 50 day moving average is $33.60 and its 200 day moving average is $35.79.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds have recently modified their holdings of the business. KBC Group NV grew its holdings in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 495 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Celldex Therapeutics during the 2nd quarter valued at about $76,000. Headlands Technologies LLC purchased a new position in Celldex Therapeutics during the 1st quarter valued at about $147,000. CANADA LIFE ASSURANCE Co boosted its holdings in Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company's stock valued at $192,000 after acquiring an additional 955 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its holdings in Celldex Therapeutics by 34.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company's stock valued at $260,000 after acquiring an additional 1,582 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.